MLB sees double-digit viewership increases in US and Japan
NEW YORK (AP) — Major League Baseball's viewer numbers in the United States and Japan during the first two months of the season have seen double-digit increases, MLB and Nielsen reported Tuesday.
ESPN's coverage is up 22%, averaging 1.74 million viewers. It is the most-watched season on ESPN through the first two months since 2017.
This might be the last year ESPN is carrying baseball after it opted out of its rights deal in February.
The MLB Tuesday package on TBS has a 16% increase. Fox Sports is up 10%, averaging 1.84 million viewers per game.
Last Saturday night's 18-2 rout by the Los Angeles Dodgers over the New York Yankees averaged 2.2 million on Fox.
The MLB.TV streaming package has seen its viewers increase 27%, with more than 7.5 billion minutes watched through Monday.
Games on the NHK channels in Japan are averaging 2.7 million. The average does not include the Tokyo Series games between the Dodgers and Chicago Cubs which began the regular season.
The ratings are on pace for MLB's most-watched regular season in Japan as the audience has increased every year since 2021.
On MLB.TV, streaming viewership has increased 27% vs 2024, which was the most-watched season in the history of the service. For games through Monday, June 2, MLB.TV has more than 7.5 billion minutes watched this season.
___
AP MLB: https://apnews.com/hub/mlb
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC Sports
5 minutes ago
- NBC Sports
Guardians at Yankees prediction: Odds, expert picks, starting pitchers, betting trends, and stats for June 5
It's Thursday, June 5, and the Guardians (33-27) are in the Bronx to take on the Yankees (37-23). Slade Cecconi is slated to take the mound for Cleveland against Max Fried for New York. The AL East-leading Yankees are hoping to bounce back from yesterday's shutout loss. The Guardian's Luis L. Ortiz was dominant through 5.2 innings. He struck out seven batters and didn't give up a run. Let's dive into the matchup and find a sweat or two. We've got all the info and analysis you need to know ahead of the game, including the latest info on the how to catch tipoff, odds, recent team performance, player stats, and of course, our predictions, picks & best bets for the game from our modeling tools and staff of experts. Follow Rotoworld Player News for the latest fantasy and betting player news and analysis all season long. Game details & how to watch Guardians at Yankees Date: Thursday, June 5, 2025 Time: 7:05PM EST Site: Yankee Stadium City: Bronx, NY Network/Streaming: YES, Guardians TV Never miss a second of the action and stay up-to-date with all the latest team stats and player news. Check out our day-by-day MLB schedule page, along with detailed matchup pages that update live in-game with every out. Odds for the Guardians at the Yankees The latest odds as of Thursday: Moneyline: Guardians (+217), Yankees (-267) Spread: Yankees -1.5 Total: 8.0 runs Probable starting pitchers for Guardians at Yankees Pitching matchup for June 5, 2025: Slade Cecconi vs. Max Fried Guardians: Slade Cecconi, (1-1, 5.28 ERA) Last outing (Los Angeles Angels, 5/31): 4.1 Innings Pitched, 5 Earned Runs Allowed, 7 Hits Allowed, 3 Walks, and 3 StrikeoutsYankees: Max Fried, (7-1, 1.92 ERA) Last outing (Los Angeles Dodgers, 5/30): 5.0 Innings Pitched, 6 Earned Runs Allowed, 8 Hits Allowed, 0 Walks, and 3 Strikeouts Guardians: Slade Cecconi, (1-1, 5.28 ERA) Last outing (Los Angeles Angels, 5/31): 4.1 Innings Pitched, 5 Earned Runs Allowed, 7 Hits Allowed, 3 Walks, and 3 Strikeouts Yankees: Max Fried, (7-1, 1.92 ERA) Last outing (Los Angeles Dodgers, 5/30): 5.0 Innings Pitched, 6 Earned Runs Allowed, 8 Hits Allowed, 0 Walks, and 3 Strikeouts Rotoworld still has you covered with all the latest MLB player news for all 30 teams. Check out the feed page right here on NBC Sports for headlines, injuries and transactions where you can filter by league, team, positions and news type! Top betting trends & insights to know ahead of Guardians at Yankees The Yankees have won 4 of their last 5 home series The Guardians' last 4 versus the Yankees have stayed under the Total The Guardians have covered in 4 of their last 5 games showing a profit of 2.95 units If you're looking for more key trends and stats around the spread, moneyline and total for every single game on the schedule today, check out our MLB Top Trends tool on NBC Sports! Expert picks & predictions for tonight's game between the Guardians and the Yankees Please bet responsibly. If you or someone you know has a gambling problem, call the National Gambling Helpline at 1-800-522-4700. Our model calculates projections around each moneyline, spread and over/under bet for every game on the MLB calendar based on data points like past performance, player matchups, ballpark information and weather forecasts. Once the model is finished running, we put its projection next to the latest betting lines for the game to arrive at a relative confidence level for each wager. Here are the best bets our model is projecting for Thursday's game between the Guardians and the Yankees: Moneyline: NBC Sports Bet is recommending a play on the New York Yankees on the Moneyline. Spread: NBC Sports Bet is leaning towards a play ATS on the Cleveland Guardians at +1.5. Total: NBC Sports Bet is leaning towards a play on the over on the Game Total of 8.0. Want even more MLB best bets and predictions from our expert staff & tools? Check out the Expert MLB Predictions page from NBC Follow our experts on socials to keep up with all the latest content from the staff: Jay Croucher (@croucherJD) Drew Dinsick (@whale_capper) Vaughn Dalzell (@VmoneySports) Brad Thomas (@MrBradThomas)
Fox News
25 minutes ago
- Fox News
ESPN anchor Jay Harris reveals prostate cancer diagnosis
ESPN broadcaster Jay Harris announced on Thursday he was diagnosed with prostate cancer and will undergo surgery next week to deal with the issue. Harris appeared on "Good Morning America" and sat down with former New York Giants star Michael Strahan to reveal his personal health battle. "I was diagnosed with prostate cancer," he told Strahan. "I'm having surgery on Tuesday. I'll be away from 'SportsCenter' for about a month to recover. Then I'm coming back better than ever." Harris said his doctor was "quite optimistic" about his prognosis. He said nothing had spread, according to his latest scans, and was hoping that once the issue is dealt with, then that would be the last of his problems. The 60-year-old sportscaster said he hoped to spread some awareness and implore men to open up more about getting regular checkups and seeing doctors who can check these things out. He also wrote about his diagnosis for ESPN. "My goal in sharing this is to join the many others who also want to normalize this conversation and hopefully provide a bit of guidance and preparation, just as it has been offered to me," he wrote. Harris said he has leaned on colleagues Hannah Storm and Brian Custer, both who have dealt with their own serious health issues over the years. He said they both provided both inspiration and "real talk" about what to expect. Fox News senior medical analyst Dr. Marc Siegel had previously called out the need for regular screenings. "[Screenings] decreased in many areas, including California, as the U.S. Preventive Services Task Force recommended against PSA as a regular screening tool, which I always disagreed with," he told Fox News Digital earlier this year. "Especially as MRI advanced, so not all elevated PSA automatically meant a biopsy." Based on the increase in prostate cancer cases across all ages, Siegel emphasized the need to "diagnose it early for better outcomes." Follow Fox News Digital's sports coverage on X, and subscribe to the Fox News Sports Huddle newsletter.
Yahoo
31 minutes ago
- Yahoo
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif., June 05, 2025--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. "This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe," said Perry Sternberg, Chief Executive Officer of Sydnexis. "This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention." The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. "The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study," said Patrick Johnson, Ph.D., President of Sydnexis. "This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date." Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. "As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic," said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. "The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide." About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital. View source version on Contacts For media inquiries, please contact: media@
